MiMedx ready to push out placental collagen AmnioFill to help treat large wounds

MiMedx Group ($MDXG), the maker of regenerative biomaterials products, plans to launch AmnioFill, a placental collagen matrix designed to treat larger acute and chronic wounds found in surgical settings.

AmnioFill, which will begin distribution later this month, will be offered in a number of sizes and configurations to meet surgical needs, the company said.

By using its Purion Process to process human amniotic membranes, the company creates tissue implants. MiMedx acquires human placentas through a donor program for mothers delivering in full-term cesarean births. In 2014, it had sold more than 275,000 of its allografts for applications including wound care, surgical, sports medicine, ophthalmic and dental indications.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Parker H. "Pete" Petit, chairman and CEO, said in a statement: "We expect that AmnioFill will be an ideal solution for physicians in the treatment of dehisced surgical wounds and other deep complex and hard-to-heal surgical wounds that require a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue."

According to statistics cited by the company, there were 53 million outpatient procedures performed in the U.S. in 2010, and although there have been huge advances in preoperative care, the rate of surgical wound dehiscence has remained at about 1% to 3%. For example, the company said, breast reconstruction incisional dehiscence rates range from 10% to 15% in a setting with radiation therapy and abdominal wall surgical dehiscences have a mortality rate as high as 45%.


Suggested Articles

Philips is cementing its commitment to becoming a healthcare technology provider, with plans to split off or sell its consumer appliances division.

A new digital health startup is exiting stealth mode with its advanced, long-lasting patient monitoring device—and touting a quick FDA clearance.

The FDA granted an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to newly diagnosed brain cancer patients.